Data / Form D filings / Juno Therapeutics, Inc.
Juno Therapeutics, Inc.: Form D filings
Juno Therapeutics, Inc., a biotechnology company in Seattle, WA, filed 7 Form D notices with the SEC between 2013 and 2017. The latest, on October 5, 2017, reports $31.1 million sold of a $31.1 million offering to 1 investor.
Find out what Juno Therapeutics, Inc. does, who founded it and who invested, beyond what the filing says. $10 of credit on sign-up, no card.
SpecStream is the live web data engine for teams and agents. It reads every Form D on SEC EDGAR the day it is filed, and this page is that reading. Ask for your own cut (a state, an industry, a size) and new filings arrive in your sheet, CRM, Slack or agent as they land.
Company details from the filing
- Address
- 400 DEXTER AVENUE NORTH, SUITE 1200, Seattle, WA, 98109
- Phone
- (206) 582-1600
- Industry
- Biotechnology
- Entity type
- Corporation
- Incorporated in
- Delaware
- Year incorporated
- 2013
- Revenue range
- $25,000,001 - $100,000,000
- Exemptions claimed
- Rule 506(c)
- SEC identifier (CIK)
- 1594864
The full lists. Form D filings in Washington: 1,095 rows, $54.75, or the new rows each week for $19 a month. Form D filings in Biotechnology: 1,568 rows, $78.40, or the new rows each week for $19 a month. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (company, CIK, street, city, state, ZIP and 4 more), which open on your screen as soon as the payment clears and come by email. For agents and scripts: every list with its row count and price is at https://specstream.ai/data/lists.json.
Form D filings
| Filed | Type | Offering | Sold | Remaining | Investors | First sale | Filing |
|---|---|---|---|---|---|---|---|
| Oct 5, 2017 | New notice | $31,091,407 | $31,091,407 | $0 | 1 | Sep 26, 2017 | sec.gov |
| Jun 29, 2017 | Amendment | Indefinite | $898,495,324 | Indefinite | 2 | Jun 29, 2015 | sec.gov |
| Jul 6, 2016 | Amendment | Indefinite | $896,803,493 | Indefinite | 2 | Jun 29, 2015 | sec.gov |
| Jul 14, 2015 | New notice | Indefinite | $849,803,496 | Indefinite | 1 | Jun 29, 2015 | sec.gov |
| Aug 14, 2014 | New notice | $133,734,641 | $85,499,985 | $48,234,656 | 22 | Aug 1, 2014 | sec.gov |
| May 8, 2014 | New notice | $97,000,000 | $28,423,971 | $68,576,029 | 34 | Apr 24, 2014 | sec.gov |
| Dec 26, 2013 | New notice | $7,145,909 | $6,667,672 | $478,237 | 21 | Dec 13, 2013 | sec.gov |
Executive officers and directors named in the filing
| Name | Role | Note in the filing |
|---|---|---|
| Mary Agnes Wilderotter | Director | |
| Hal J. Barron | Director | |
| Richard J. Klausner | Director, Promoter | |
| Anthony J. Evnin | Director | |
| Robert J. Nelsen | Director, Promoter | |
| Sunil Agarwal | Executive Officer | |
| Steven Harr | Executive Officer | |
| Robert Azelby | Executive Officer | |
| Thomas Agnes Daniel | Director | |
| Howard J. Pien | Director | |
| Hans Bishop | Executive Officer, Director, Promoter | |
| Bernard J. Cassidy | Executive Officer | |
| Rupert Agnes Vessey | Director | |
| Jay J. Flatley | Director |
Other biotechnology companies in Washington that filed recently
- Key Proteo, Inc. $2.3 million · Oct 23, 2026
- Inmedix, Inc. $4 million · Oct 22, 2026
- Q-Immune, Inc. $25,000 · Sep 28, 2026
- Hexamer Therapeutics, Inc $500,000 · Sep 15, 2026
- MalarVx, Inc. $125,000 · Aug 25, 2026
- Strella Biotechnology, Inc. $1.8 million · Aug 14, 2026
Every Form D from the week of Oct 2, 2017 · All recent filings in Washington · All recent Biotechnology filings
Read from SEC EDGAR. Amount sold is what Juno Therapeutics, Inc. reported on the day it filed; on an offering that is still open, a later amendment can raise it. Free to reuse with credit to SpecStream under CC BY 4.0.
$10 of credit on sign-up, no card.